Compare AMRO & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRO | HUMA |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.1M | 165.7M |
| IPO Year | 2026 | 2020 |
| Metric | AMRO | HUMA |
|---|---|---|
| Price | $6.33 | $0.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.63 |
| AVG Volume (30 Days) | 453.9K | ★ 5.7M |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | $374.17 | $72.32 |
| Revenue Next Year | $81.38 | $518.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.99 | $0.34 |
| 52 Week High | $8.64 | $1.53 |
| Indicator | AMRO | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 63.57 | 50.41 |
| Support Level | $5.13 | $0.36 |
| Resistance Level | $6.60 | $0.48 |
| Average True Range (ATR) | 0.77 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 88.51 | 54.56 |
Amaero Inc specializes in manufacturing high-performance powders and near-net-shape components using additive manufacturing and HIP technologies, ensuring precision, material integrity, and reduced times for critical applications. It serves in industries of Aerospace, Defense, Energy, Oil & Gas, and Others. The group leverages cutting-edge gas atomization and hot isostatic pressing (HIP) technologies to create high-performance components that reduce porosity and improve material integrity. Its focus is on reshoring critical materials production and defense manufacturing, offering high-value refractory, specialty, and titanium alloyed powders.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.